EyePoint Pharmaceuticals Announces New Stock Offering
In a significant move, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company dedicated to enhancing therapies for patients with serious retinal diseases, has commenced an underwritten public offering of $150 million worth of its common stock. This offering is entirely from the company’s shares, reflecting EyePoint's commitment to expanding its innovative solutions.
Details of the Offering
The offering is being managed by top financial institutions including J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities. All parties are poised to navigate through market conditions to finalize the offering, though specific terms and timelines remain uncertain.
Use of Proceeds
The net proceeds from this offering are earmarked for advancing the clinical development of DURAVYU™, a treatment aimed at wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, these proceeds will support the development of EyePoint’s earlier-stage pipeline initiatives, as well as general corporate purposes.
Regulatory Insights
The securities being offered are part of a shelf registration statement that was filed with the Securities and Exchange Commission, allowing for a seamless process as EyePoint looks to mobilize funds efficiently.
Prospectus Information
A prospectus supplement, detailing the terms of the offering, will be filed with the SEC. Interested parties can find more information about the offering terms through the SEC’s official website or can contact the involved financial institutions directly for their specific requirements.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc., operating under NASDAQ: EYPT, is a trailblazer in the realm of biopharmaceuticals, focusing on innovating treatments to enhance the quality of life for those affected by serious retinal diseases. Its leading product, DURAVYU™, employs a unique sustained delivery mechanism to combat VEGF-mediated retinal conditions. Current clinical trials are pivotal, with anticipated data releases showcasing the efficacy of DURAVYU.
Continued Commitment to Innovation
With a history of developing effective therapies, EyePoint has successfully brought four drugs to market over the past three decades, impacting the lives of tens of thousands of patients. This commitment to innovation is at the heart of EyePoint's mission.
Future Directions
As EyePoint looks ahead, it remains focused on building partnerships within the retina community, striving to enhance patient outcomes while creating lasting value. The company's headquarters are in Watertown, Massachusetts, alongside a commercial manufacturing facility located in Northbridge.
What is Vorolanib?
Vorolanib is a key component in EyePoint's drug development, licensed exclusively for treating various ophthalmic diseases outside of specific regions. This compound is integral to the efficacy of DURAVYU™, which has gained conditional acceptance by the FDA as a proprietary name.
Contact Information
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Email: Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
Email: aphillips@greenroompr.com
Frequently Asked Questions
What is the purpose of EyePoint's new offering?
The offering aims to fund clinical development of DURAVYU™ and other initiatives, supporting the company’s expansion in retinal disease treatments.
Who is managing the stock offering?
J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are the joint book running managers of the offering.
What are the uses of the proceeds from this offering?
The proceeds will be allocated to advancing clinical trials and supporting general corporate purposes at EyePoint Pharmaceuticals.
Is DURAVYU™ approved by the FDA?
The FDA has conditionally accepted DURAVYU™ as a proprietary name, but the product is still under investigation and not yet approved.
Where is EyePoint Pharmaceuticals located?
EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, and operates a commercial manufacturing facility in Northbridge, Massachusetts.
